MarginsXMarginsX
Home › Markets › Health Care › URGN

UroGen Pharma Ltd. (URGN)

URGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$28.10
+7.33% on the day
Market cap
$1.4B
Small cap
Revenue · 2025
$109.8M
+21.4% on 2024
Net income · 2025
-$153.5M
-139.8% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1668243/000143774926006234/0001437749-26-006234-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerURGN on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryIsrael
IPO year2017
SEC CIK0001668243
SEC industry codePharmaceutical Preparations
Incorporated inIsrael

Financials · 2025

LineValue
Revenue$109.8M
Net income-$153.5M
Operating income-$124.9M
Net margin-139.8%
Operating margin-113.7%
Revenue growth+21.4%
Cash$110.7M
Total assets$200.5M
P/E (computed)Net income was not positive
P/S (computed)12.6×

Warning signs

Cash runway
7.8 months
$85.6M cash at September 30, 2026
Share count, 1 year
+4.8%
2025-10-31 to 2026-10-28 · +58.9% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$4.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.
"In accordance with the accounting guidance related to the presentation of financial statements, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for the next 12 months from the date the financial statements are issued."
10-Q 2026-11-04
Cash and burn$85.6M cash; operating cash flow -$33.0M a quarter.Report 2026-09-30
Shares outstanding49,047,823 (2026-10-28); 46,808,892 a year earlier; 30,866,320 three years earlier.Cover page 2026-10-28
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Florham Park, New Jersey, United StatesPCAOB Form AP 2026-03-18
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $4.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$89.0M-$1.5M-$15.2M$85.6M$200.0M$250.3M10-Q 2026-11-04
Q2 2026
2026-06-30
$72.5M-$14.4M-$33.0M$79.1M$200.0M$188.7M10-Q 2026-08-05
Q1 2026
2026-03-31
$51.0M-$23.6M-$45.3M$110.0M$200.0M$140.5M10-Q 2026-05-06
Q4 2025
2025-12-31
$37.8M-$26.4M-$38.3M$110.7M$125.0M$109.8M10-K 2026-03-02
Q3 2025
2025-09-30
$27.5M-$33.3M-$42.3M$90.0M$122.1M$96.5M10-Q 2026-11-04
Q2 2025
2025-06-30
$24.2M-$49.9M-$39.8M$92.9M$122.5M$94.2M10-Q 2026-08-05
Q1 2025
2025-03-31
$20.3M-$43.8M-$42.0M$104.0M$122.1M$91.9M10-Q 2026-05-06
Q4 2024
2024-12-31
$24.6M-$37.5M-$13.6M$172.0M$121.7M$90.4M10-K 2025-03-10

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-11-06
Latest annual report
FORM 10-K
10-K2026-03-02
Latest quarterly / interim
FORM 10-Q
10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-04
Latest proxy
FORM DEF 14A
DEF 14A2026-04-30

Source: SEC EDGAR submissions feed, 584 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.8%
1 month-31.6%
3 months-45.6%
Year to date+11.8%
1 year+9.4%
From 52-week high-47.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
LBRXLB Pharmaceuticals Inc$42.99-0.05%$1.4B
DMRADamora Therapeutics Inc.$22.50+4.14%$1.4B
TYRATyra Biosciences Inc.$19.74-1.42%$1.4B
ANABAnaptysBio Inc.$45.73-1.12%$1.4B
NUVBNuvation Bio Inc.$3.84-3.76%$1.4B
GENBGenerate Biomedicines Inc.$10.49-13.09%$1.4B
PAHCPhibro Animal Health Corporation$35.02-2.64%$1.4B
GPCRStructure Therapeutics Inc.$18.57-7.15%$1.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier